The Kim Iversen Show
Aug. 1, 2022
Biden Pushes More Pills and Shots Despite Rebounds
There’s no data on Paxlovid on those who have had COVID shots. Fauci also suffered a rebound case, which was worse than his first go around.
What’s Really Driving COVID ‘Rebound’ After Paxlovid?
— There’s only one way to find out
In the early days of the pandemic there was an understandable rush to define and optimally treat COVID-19. Anecdotal evidence and the opinions of eminent scientists and non-scientists overwhelmed social and mainstream media platforms only to eventually be overruled by the results of careful, scientific analyses and well-designed clinical trials. Now, more than 2 years into the pandemic, we must return to the standard of careful and thorough analyses for all interventions and treatments.
The debate about “COVID-19 rebound” after nirmatrelvir/ritonavir (Paxlovid) treatment is one of these timely areas warranting further investigation. Continuing down the current path of uncertainty has consequences for how and by whom this antiviral should be used. However, by applying lessons learned from the early days of the pandemic — including acknowledging the importance of randomized controlled trials (RCTs) — we can avoid repeating the same mistakes. To do this, it is necessary to start by defining the question, identifying current knowledge gaps, and only then can one propose scientific solutions to bring a rapid resolution to the COVID-19 rebound controversy. (See link for article)
Aside from the ever-mounting cases of Paxlovid rebound, Drs. Marik and Kory have been shouting from the rooftops about the dangers of taking Paxlovid. Said Dr. Kory in another recent Op-Ed:
“The problems with Paxlovid are no secret. FDA granted Pfizer emergency use authorization for the drug after a single trial with questionable results. The medicine has many contraindications, meaning it can’t be taken by someone who simultaneously would be taking certain anti-depressants, anti-seizure, anti-psychotic, cholesterol, or blood pressure medications. Furthermore, many Americans cannot take Paxlovid, given that nearly half of adults have cardiovascular disease.
“Consider the Food and Drug Administration’s recent decision allowing pharmacists to play doctor and prescribe Pfizer’s anti-viral treatment Paxlovid. No pharmacist could ever safely dispense a novel medicine with an unprecedented amount of drug interactions without in-depth knowledge of the severity of the patient’s medical problems or the critical necessity of each of their other medicines.
“Biden’s policy of a toxic jab in every arm and a pricey pill in every mouth needs an overhaul.”
Early treatment works. The FLCCC Protocols work. And hundreds of thousands are alive today to prove it.